Dificid (Fidaxomicin) Patent Expiration, LOE Window & CMS Spending
Dificid (Fidaxomicin) by Merck & Co.: FDA Orange Book core substance LOE 2028-01-31, 5 AB generics, $176.5M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N201699 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2028-01-31 |
| Last Listed Patent or Exclusivity Date | 2028-01-31 |
| Orange Book Patents (*PED Extensions) | 8 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $176.5M |
| 2024 Medicare Part D Spend | $153.8M |
| 2024 Medicaid Spend | $22.7M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 16.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.